Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
kb707
Melanoma
Krystal Biotech, Inc.P1/2CC (47)
Navitoclax
Melanoma
National Cancer Institute (NCI)P1/2CC (47)
st101
Melanoma
Sapience TherapeuticsP1/2CC (47)
Taselisib
Melanoma
National Cancer Institute (NCI)P2CC (47)
Acetazolamide
Melanoma
Obsidian Therapeutics, Inc.P1/2CC (46)
Camu Camu
Melanoma
Centre hospitalier de l'Université de Montréal (CHUM)P1CC (46)
Copanlisib
Melanoma
National Cancer Institute (NCI)P2CC (46)
Cypep-1
Melanoma
Cytovation ASP1/2CC (46)
Monoclonal Antibody Trk-950
Melanoma
Toray Industries, IncP1/2CC (46)
Obinutuzumab
Melanoma
Simcha IL-18, Inc.P1/2CC (46)
Obx-115
Melanoma
Obsidian Therapeutics, Inc.P1/2CC (46)
Recombinant Hgm-Csf Herpes Simplex Virus
Melanoma
Peking University Cancer Hospital & InstituteP1CC (46)
Recombinant Human Interferon Α1B
Melanoma
Xijing HospitalP1/2CC (46)
Sitravatinib
Melanoma
Peking University Cancer Hospital & InstituteP2CC (46)
Tbio-4101
Melanoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (46)
a2/4-1bbl melanoma vaccine
Melanoma
Hadassah Medical OrganizationP1/2CC (45)
Amt-253 For
Melanoma
Multitude Therapeutics Inc.P1/2CC (45)
Benmelstobart
Melanoma
Beijing Tide Pharmaceutical Co., LtdP1/2CC (45)
Cedazuridine
Melanoma
University of Colorado, DenverP1/2CC (45)
gm103
Melanoma
GeneMedicine Co., Ltd.P1/2CC (45)
Nogapendekin Alfa Inbakicept
Melanoma
ImmunityBio, Inc.P2CC (45)
tcc1727
Melanoma
Beijing Tide Pharmaceutical Co., LtdP1/2CC (45)
vv1
Melanoma
Vyriad, Inc.P2CC (45)
Cetuximab
Melanoma
C4 Therapeutics, Inc.P1CC (44)
e-602
Melanoma
Palleon Pharmaceuticals, Inc.P1/2CC (44)
e7386
Melanoma
Eisai Inc.P1/2CC (44)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-59*01 (99.0%) -(Ighd) -Ighj3*02 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-11*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Melanoma
Kineta Inc.P1/2CC (44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Melanoma
National Cancer Institute (NCI)P1/2CC (44)
Lorigerlimab
Melanoma
MacroGenicsP1CC (44)
L-Valine, S-L-Valyl-(3S,4E)-3-Hydroxy-7-Mercapto-4-Heptenonyl-2-(Aminomethyl)-4-Thiazolecarbonyl-2-Methylalanyl-, (5?2)-Lactone, Benzenesulfonate (1:1)
Melanoma
OnKure, Inc.P1/2CC (44)
Midazolam
Melanoma
PfizerP1CC (44)
Tigilanol Tiglate
Melanoma
QBiotics Group LimitedP2CC (44)
Tovorafenib
Melanoma
Day One Biopharmaceuticals, Inc.P2CC (44)
Tucidinostat
Melanoma
Peking University Cancer Hospital & InstituteP1/2CC (44)
Vedolizumab
Melanoma
M.D. Anderson Cancer CenterP1/2CC (44)
Vobramitamab Duocarmazine
Melanoma
MacroGenicsP2CC (44)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-
Melanoma
Nurix Therapeutics, Inc.P1CC (43)
Adp-Tilil7
Melanoma
Inge Marie SvaneP1CC (43)
Danburstotug
Melanoma
Mayo ClinicP1CC (43)
Dcb-Bo1301
Melanoma
Chung Mei Biopharma Co., LtdP1/2CC (43)
fyb206
Melanoma
Formycon AGP1CC (43)
Ibrutinib
Melanoma
Mayo ClinicP1CC (43)
Lbl-024 For
Melanoma
Nanjing Leads Biolabs Co.,LtdP1/2CC (43)
Proleukin
Melanoma
Inge Marie SvaneP1CC (43)
Riluzole
Melanoma
National Cancer Institute (NCI)P1CC (43)
Sonidegib
Melanoma
Mayo ClinicP1CC (43)
Tacrolimus
Melanoma
National Cancer Institute (NCI)P1CC (43)
vet3-tgi
Melanoma
KaliVir ImmunotherapeuticsP1CC (43)
Bavunalimab
Melanoma
University of California, San FranciscoP1CC (42)
Adoptive Therapy With Autologous Mc2 Tcr T Cells
Melanoma
Erasmus Medical CenterP1/2CC (41)
Showing 201 to 250 of 435 assets
PreviousPage 5 of 9Next